TrinityPoint Wealth LLC Has $3.76 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

TrinityPoint Wealth LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,719 shares of the biopharmaceutical company's stock after selling 2,887 shares during the period. TrinityPoint Wealth LLC's holdings in Gilead Sciences were worth $3,761,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in Gilead Sciences in the 4th quarter worth approximately $1,789,254,000. FMR LLC raised its position in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Northern Trust Corp lifted its position in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Gilead Sciences in the 4th quarter worth about $207,340,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.8 %

Shares of GILD traded down $0.87 during trading hours on Monday, hitting $102.81. 5,486,348 shares of the company were exchanged, compared to its average volume of 7,519,327. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market cap of $128.02 billion, a PE ratio of 277.86, a PEG ratio of 0.71 and a beta of 0.26. The firm's 50 day moving average is $108.69 and its 200-day moving average is $98.99. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The company's revenue was down .3% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.07%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 160,605 shares of company stock valued at $16,718,136 in the last quarter. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on GILD shares. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.